The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
uniQure N.V(NASDAQ:QURE) 
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also e...
Website: http://www.uniqure.com
Founded: 1998
Full Time Employees: 248
Sector: Healthcare
Industry: Biotechnology
uniQure N.V Days Payable Outstanding ttm (DPO)
uniQure N.V Days Receivable Outstanding ttm (DSO)
uniQure N.V Days Inventory Outstanding ttm (DIO)
uniQure N.V Op Cashflow Per Share ttm
uniQure N.V Free Cashflow Per Share ttm
uniQure N.V Cash Per Share ttm
uniQure N.V P/S ratio ttm
uniQure N.V (GAAP) P/E ratio ttm
uniQure N.V P/B ratio ttm
No extra charts and metrics for this ticker.